View in EDS PDF Full Text

Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.

Saved in:
Bibliographic Details
Title: Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.
Authors: Stanley AM; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Aksyuk AA; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Wilkins D; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Green JA; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Lan D; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Shoemaker K; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States., Tieu HV; Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian Columbia University Irving Medical Center, New York, NY, United States.; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States., Sobieszczyk ME; Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian/Columbia University Irving Medical Center, New York, NY, United States., Falsey AR; Department of Medicine, Infectious Diseases, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.; Infectious Disease, Rochester Regional Health, Rochester, NY, United States., Kelly EJ; Formerly Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Source: Frontiers in immunology [Front Immunol] 2024 May 17; Vol. 15, pp. 1401728. Date of Electronic Publication: 2024 May 17 (Print Publication: 2024).
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38827749
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Stanley+AM%22">Stanley AM</searchLink>; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Aksyuk+AA%22">Aksyuk AA</searchLink>; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Wilkins+D%22">Wilkins D</searchLink>; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Green+JA%22">Green JA</searchLink>; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Lan+D%22">Lan D</searchLink>; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Shoemaker+K%22">Shoemaker K</searchLink>; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.<br /><searchLink fieldCode="AU" term="%22Tieu+HV%22">Tieu HV</searchLink>; Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian Columbia University Irving Medical Center, New York, NY, United States.; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States.<br /><searchLink fieldCode="AU" term="%22Sobieszczyk+ME%22">Sobieszczyk ME</searchLink>; Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian/Columbia University Irving Medical Center, New York, NY, United States.<br /><searchLink fieldCode="AU" term="%22Falsey+AR%22">Falsey AR</searchLink>; Department of Medicine, Infectious Diseases, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.; Infectious Disease, Rochester Regional Health, Rochester, NY, United States.<br /><searchLink fieldCode="AU" term="%22Kelly+EJ%22">Kelly EJ</searchLink>; Formerly Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2024 May 17; Vol. 15, pp. 1401728. <i>Date of Electronic Publication: </i>2024 May 17 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38827749
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2024.1401728
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1401728
    Titles:
      – TitleFull: Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Stanley AM
      – PersonEntity:
          Name:
            NameFull: Aksyuk AA
      – PersonEntity:
          Name:
            NameFull: Wilkins D
      – PersonEntity:
          Name:
            NameFull: Green JA
      – PersonEntity:
          Name:
            NameFull: Lan D
      – PersonEntity:
          Name:
            NameFull: Shoemaker K
      – PersonEntity:
          Name:
            NameFull: Tieu HV
      – PersonEntity:
          Name:
            NameFull: Sobieszczyk ME
      – PersonEntity:
          Name:
            NameFull: Falsey AR
      – PersonEntity:
          Name:
            NameFull: Kelly EJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 05
              Text: 2024 May 17
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1